EP 0904082 A4 20010926 - COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE

Title (en)

COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE

Title (de)

KOMBINATIONSTHERAPIE ZUR VERMINDERUNG DER MIT HERZ-KREISLAUFERKRANKUNGEN EINHERGENDEN RISIKEN

Title (fr)

THERAPIE D'ASSOCIATION DESTINEE A REDUIRE LES RISQUES LIES A UNE MALADIE CARDIO-VASCULAIRE

Publication

EP 0904082 A4 20010926 (EN)

Application

EP 97918595 A 19970414

Priority

GB 9612082 A 19960610
GB 9616804 A 19960809
US 9706127 W 19970414
US 1568996 P 19960417
US 2097796 P 19960624

Abstract (en)

[origin: WO9738694A1] The instant invention provides methods for preventing or reducing the risk of developing atherosclerosis, as well as for halting or slowing the progression of atherosclerotic disease once it has become clinically evident, comprising the administration of a therapeutically effective amount of an HMG-CoA RI in combination with folic acid or a pharmaceutically acceptable salt or ester thereof to a person who is at risk of developing atherosclerosis or who already has atherosclerotic disease.

IPC 1-7

A61K 31/53; A61K 31/35; A61K 31/505; A61P 3/06; A61P 9/10

IPC 8 full level

A61K 45/00 (2006.01); A61K 31/00 (2006.01); A61K 31/365 (2006.01); A61K 31/366 (2006.01); A61K 31/505 (2006.01); A61K 31/519 (2006.01); A61K 31/529 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01)

CPC (source: EP)

A61K 31/505 (2013.01); A61P 3/06 (2017.12); A61P 9/00 (2017.12); A61P 9/10 (2017.12)

C-Set (source: EP)

Citation (search report)

[X] US 5084482 A 19920128 - HIRSCH GERALD P [US], et al
[Y] DE 4326698 A1 19950309 - PUETTER MEDICE CHEM PHARM [DE]
[X] DOBS A. ET AL.: "Lipid-lowering diets in patients, a new HMG-CoA reductase inhibitor: compliance and adequacy", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 54, no. 4, October 1991 (1991-10-01), pages 696-700, XP001006920
[X] FROHLICH J J: "LIPOPROTEINS AND HOMOCYST(E)INE AS RISK FACTORS FOR ATHEROSCLEROSIS:ASSESSMENT AND TREATMENT", CANADIAN JOURNAL OF CARDIOLOGY,XX,PULSUS GROUP, INC, vol. 11, no. SUPPL. C, 1995, pages 18C - 23C, XP000910760, ISSN: 0828-282X
[Y] "The Merck Manual of Diagnosis and Therapy", 1992, XP002170578
[Y] BOUSHEY C. ET AL.: "A quantitative assessment of plasma homocysteine as a risk factor for vascular disease", JAMA, vol. 274, no. 13, 4 October 1995 (1995-10-04), pages 1049 - 1057, XP001005592
[Y] MAYER E L ET AL: "HOMOCYSTEINE AND CORONARY ATHEROSCLEROSIS", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,XX,XX, vol. 27, no. 3, 1 March 1996 (1996-03-01), pages 517 - 527, XP000990693, ISSN: 0735-1097
[A] BERG VAN DEN M ET AL: "COMBINED VITAMIN B6 PLUS FOLIC ACID THERAPY IN YOUNG PATIENTS WITH ARTERIOSCLEROSIS AND HYPERHOMOCYSTEINEMIA", JOURNAL OF VASCULAR SURGERY,US,ST. LOUIS, MO, vol. 20, no. 6, December 1994 (1994-12-01), pages 933 - 940, XP000853837, ISSN: 0741-5214
[A] FEHER M D ET AL: "LONG-TERM SAFETY OF STATIN-FIBRATE COMBINATION TREATMENT IN THE MANAGEMENT OF HYPERCHOLESTEROLAEMIA IN PATIENTS WITH CORONARY ARTERY DISEASE", BRITISH HEART JOURNAL,BRITISH MEDICAL ASSOCIATION, LONDON,GB, vol. 74, no. 1, 1995, pages 14 - 17, XP000925445, ISSN: 0007-0769
[A] TONSTAD S: "Low dose colestipol in adolescents with familial hypercholesterolaemia", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 74, no. 2, February 1996 (1996-02-01), pages 157 - 160, XP001000237
See references of WO 9738694A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

WO 9738694 A1 19971023; AU 2666597 A 19971107; AU 732465 B2 20010426; CA 2251972 A1 19971023; EP 0904082 A1 19990331; EP 0904082 A4 20010926; JP 2000508659 A 20000711

DOCDB simple family (application)

US 9706127 W 19970414; AU 2666597 A 19970414; CA 2251972 A 19970414; EP 97918595 A 19970414; JP 53726497 A 19970414